Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

212.24 -0.31 (-0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,299,094
Open 212.90
Bid (Size) 212.35 (1)
Ask (Size) 213.74 (10)
Prev. Close 212.55
Today's Range 212.15 - 212.97
52wk Range 116.08 - 217.08
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher. 
Via InvestorPlace
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
+64.91%
+64.91%
1 Month
+2.55%
+2.55%
3 Month
+10.81%
+10.81%
6 Month
+4.51%
+4.51%
1 Year
+54.11%
+54.11%

More News

Read More
Seagen Unusual Options Activity
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
Why Is Seagen Stock Trading Higher Today?
Via Benzinga
(SGEN) - Analyzing Seagen's Short Interest
Via Benzinga
Check Out What Whales Are Doing With SGEN
Via Benzinga
Check Out What Whales Are Doing With SGEN
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
Via Investor's Business Daily
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
From Seagen Inc.
Via Business Wire
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Check Out What Whales Are Doing With SGEN
Via Benzinga
Looking Into Seagen's Recent Short Interest
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Via InvestorPlace
Why Is Cancer Focused Nurix Therapeutics Stock Trading Higher Today?
Via Benzinga
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst
Via Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Via The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
Via Benzinga
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
From Seagen Inc.
Via Business Wire
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via Business Wire
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.